Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing women’s reproductive health products in the United States. More Details
+ 1 more risk
Slightly overvalued with imperfect balance sheet.
Share Price & News
How has Daré Bioscience's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: DARE's share price has been volatile over the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: DARE exceeded the US Medical Equipment industry which returned 14.6% over the past year.
Return vs Market: DARE exceeded the US Market which returned 12.7% over the past year.
Price Volatility Vs. Market
How volatile is Daré Bioscience's share price compared to the market and industry in the last 5 years?
Simply Wall St News
6 months ago | Simply Wall StWhat Kind Of Shareholder Owns Most Daré Bioscience, Inc. (NASDAQ:DARE) Stock?
7 months ago | Simply Wall StDoes Daré Bioscience, Inc. (NASDAQ:DARE) Have A Volatile Share Price?
8 months ago | Simply Wall StWho Has Been Buying Daré Bioscience, Inc. (NASDAQ:DARE) Shares?
Is Daré Bioscience undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: DARE ($1.01) is trading below our estimate of fair value ($19.19)
Significantly Below Fair Value: DARE is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: DARE is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: DARE is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate DARE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: DARE is overvalued based on its PB Ratio (92.6x) compared to the US Medical Equipment industry average (3.7x).
How is Daré Bioscience forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DARE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: DARE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: DARE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if DARE's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if DARE's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if DARE's Return on Equity is forecast to be high in 3 years time
How has Daré Bioscience performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DARE is currently unprofitable.
Growing Profit Margin: DARE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: DARE is unprofitable, and losses have increased over the past 5 years at a rate of 39.3% per year.
Accelerating Growth: Unable to compare DARE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DARE is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.2%).
Return on Equity
High ROE: DARE has a negative Return on Equity (-5987.37%), as it is currently unprofitable.
How is Daré Bioscience's financial position?
Financial Position Analysis
Short Term Liabilities: DARE's short term assets ($7.8M) exceed its short term liabilities ($6.1M).
Long Term Liabilities: DARE's short term assets ($7.8M) exceed its long term liabilities ($2.2M).
Debt to Equity History and Analysis
Debt Level: DARE's debt to equity ratio (118%) is considered high.
Reducing Debt: Insufficient data to determine if DARE's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: DARE has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: DARE has less than a year of cash runway if free cash flow continues to reduce at historical rates of 60.2% each year
What is Daré Bioscience current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate DARE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate DARE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DARE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DARE's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DARE's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sabrina Johnson (53 yo)
Ms. Sabrina Martucci Johnson is the Founder and Chief Executive Officer of Dare Bioscience and serves as its President. Ms. Johnson serves as Secretary and Treasurer at Kyalin Biosciences, Inc. Ms. Johnson ...
CEO Compensation Analysis
Compensation vs Market: Sabrina's total compensation ($USD628.75K) is about average for companies of similar size in the US market ($USD601.89K).
Compensation vs Earnings: Sabrina's compensation has increased whilst the company is unprofitable.
|CFO & Secretary||3.17yrs||US$412.72k||1.41% |
|Vice President of Operations||5.67yrs||no data||0% |
|Vice President of Accounting & Finance||no data||no data||no data|
|Chief Scientific Officer||2.25yrs||no data||no data|
|Chief Strategy Officer||2.33yrs||no data||no data|
|Global Head of Regulatory Affairs||2.25yrs||no data||no data|
|Controller||no data||no data||no data|
Experienced Management: DARE's management team is considered experienced (2.8 years average tenure).
|Chairman of the Board||6.67yrs||US$83.50k||0.033% |
|Member of Scientific Advisory Board||1.5yrs||no data||no data|
|Independent Director||5.92yrs||US$64.31k||0% |
|Independent Director||0.83yr||US$37.51k||no data|
|Independent Director||3.17yrs||US$66.81k||0.78% |
|Independent Director||2.42yrs||US$61.36k||0% |
|Independent Director||2yrs||US$70.91k||0.0016% |
Experienced Board: DARE's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 89.1%.
Daré Bioscience, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Daré Bioscience, Inc.
- Ticker: DARE
- Exchange: NasdaqCM
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$31.868m
- Shares outstanding: 31.55m
- Website: https://www.darebioscience.com
Number of Employees
- Daré Bioscience, Inc.
- 3655 Nobel Drive
- Suite 260
- San Diego
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|DARE||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Jul 2017|
|1221||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jul 2017|
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing women’s reproductive health products in the United States. The company intends to develop therapies in ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/23 07:10|
|End of Day Share Price||2020/09/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.